Randomized, placebo-controlled trial of lazaroid effects on severe acute pancreatitis in rats

Critical Care Medicine

Volumn 29, Issue 4, 2001, Pages 861-869

  Schulz, Hans Ulrich ^a,c   Hoenl, Hanns ^a   Schrader, Thomas ^a   Kropf, Siegfried ^a   Halangk, Walter ^a   Ochmann, Christian ^a   Matthias, Rainer ^a   Letko, Gerold ^a   Roessner, Albert ^a   Lippert, Hans ^a   Niederau, Claus ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b St Josef Hospital Oberhausen   (Germany)

^c Klinik fuer Chirurgie   (Germany)

Author keywords

Acute pancreatitis; Antioxidants; Interleukin 1 ; Lazaroids; Lethality; Oxidative stress; Proteases; Rat; Severity; Taurocholate model; Therapy; Trypsin; Trypsinogen; Tumor necrosis factor

Indexed keywords

2 [[4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]METHYL] 3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 6 OL; 21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; 21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; LAZAROID; METHYLPREDNISOLONE; PLACEBO; RINGER LACTATE SOLUTION; TAUROCHOLIC ACID; TRYPSINOGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PANCREATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; EDEMA; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 0035047378     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200104000-00035     Document Type: Article

References (60)

1. Treatment of acute pancreatitis: Comparison of animal and human studies
2. Oxidative stress in acute pancreatitis
3. Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation
4. Lazaroids: CNS pharmacology and current research
5. Lazaroids protect isolated rat pancreatic acinar cells against damage induced by free radicals
6. Potential therapeutic value of lazaroids in endotoxemia and other forms of sepsis
7. Gastric injury induced by ethanol and ischemiareperfusion in the rat. Differing roles for lipid peroxidation and oxygen radicals
8. Lazaroid U-74500A for warm ischemia and reperfusion injury of the canine small intestine
9. Anti-inflammatory effects of U74389F in a rat model of intestinal ischemia/reperfusion injury
10. Protective effects of a novel nonglucocorticoid 21-aminosteroid (U74006F) during traumatic shock in rats
11. Melatonin and a 21-aminosteroid attenuate shock after hemorrhage but differentially affect serum cytokines
12. Effects of the lazaroid, tirilazad mesylate, on sepsis-induced acute lung injury in minipigs
13. Attenuation of multiple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G
14. Pancreatic exocrine secretion in acute experimental pancreatitis
15. Experimental pancreatitis in the rat. Sodium taurocholate-induced acute haemorrhagic pancreatitis
16. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats
17. Effect of temporary ischemia upon development and histological patterns of acute pancreatitis in the rat
18. A simple, rapid, and sensitive DNA assay procedure
19. Fluorimetric assays of proteolytic enzymes
20. Intrapancreatic zymogen activation and levels of ATP and glutathione during caerulein pancreatitis in rats
21. Experimental pancreatitis in the rat. Development of pancreatic necrosis, ischemia and edema after intraductal sodium taurocholate injection
22. The role of oxygen-derived free radicals in two models of experimental acute pancreatitis: Effects of catalase, superoxide dismutase, dimethylsulfoxide, and allopurinol
23. Occurrence of oxidatively modified proteins: An early event in experimental acute pancreatitis
24. Acute pancreatic lesions in patients treated with ACTH and adrenal corticoids
25. Pancreatitis in children following adrenal cortico-steroid therapy
26. Acute pancreatitis associated with steroid therapy
27. Dual effects of hydrocortisone on exocrine rat pancreas
28. Glucocorticoids effects on exocrine pancreatic secretion in caerulein-induced acute pancreatitis in the rat
29. Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone
30. Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein
31. Effect of interleukin-1 (IL-1), prednisolone and indomethacin on caerulein-induced acute pancreatitis in rats
32. Effects on peritoneal proteolysis and hemodynamics by high doses of methyl-prednisolone in experimental acute pancreatitis
33. Methylprednisolone in acute canine hemorrhagic pancreatitis
34. The effects of glucocorticoids and a glucocorticoid antagonist (RU 38486) on Na-taurocholate-induced acute pancreatitis in rat
35. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature
36. Oxidative stress. An early phenomenon characteristic of acute experimental pancreatitis
37. The involvement of oxygen radicals in acute pancreatitis
38. The effect of platelet activating factor antagonist (BN 52021) on cerulein-induced acute pancreatitis with reference to oxygen radicals
39. Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse
40. Beneficial effects of L-2-oxothiazolidine-4-carboxylate on cerulein pancreatitis in mice
41. Increased pancreatic metallothionein and glutathione levels: Protecting against cerulein and taurocholate-induced acute pancreatitis in rats
42. Clinical trial of 24 hours' treatment with glutathione precursors in acute pancreatitis
43. Standards of morphological evaluation and histological grading in experimental acute pancreatitis
44. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis
45. Anti-TNFα therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat
46. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis
47. Inhibition of tumor necrosis factor-α release in rat experimental endotoxemia by treatment with the 21-aminosteroid U-74389G
48. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis
49. Active interleukin-1 receptor required for maximal progression of acute pancreatitis
50. Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism
51. Protease-antiprotease balance in serum and pancreatic tissue in acute experimental pancreatitis in rats
52. Protease-antiprotease imbalance, hemodynamic and regional blood flow changes in experimental pancreatitis
53. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis
54. Trypsinogen-activation peptides in experimental rat pancreatitis: Prognostic implications and histopathologic correlates
55. Activation of trypsinogen in experimental models of acute pancreatitis in rats
56. Effect of microcirculatory perfusion on distribution of trypsinogen activation peptides in acute experimental pancreatitis
57. Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect
58. Local administration of human pancreatic secretory trypsin inhibitor prevents the development of experimental acute pancreatitis in rats and dogs
59. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis